Topiramate effectiveness in Prader-Willi syndrome

Prader-Willi syndrome is a neurologic disorder caused by a mutation on chromosome 15. It is characterized by short stature, obesity, mild-to-moderate mental retardation, and multiple behavior problems including mood, self-abusive behavior, and compulsive-eating disorder. These behaviors have detrime...

Full description

Saved in:
Bibliographic Details
Published inPediatric neurology Vol. 28; no. 2; pp. 130 - 133
Main Authors Smathers, Sarah A, Wilson, Jacquelyn G, Nigro, Michael A
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.02.2003
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Prader-Willi syndrome is a neurologic disorder caused by a mutation on chromosome 15. It is characterized by short stature, obesity, mild-to-moderate mental retardation, and multiple behavior problems including mood, self-abusive behavior, and compulsive-eating disorder. These behaviors have detrimental effects on the mental and physical health of patients with Prader-Willi syndrome. This study evaluates the effectiveness of a new antiepileptic medication, topiramate, on behavior, mood, and compulsive-eating disorder associated with Prader-Willi syndrome. Recent studies have indicated that topiramate affects behavior, as well as reducing appetite and weight in some patients. We evaluated seven patients with Prader-Willi syndrome and determined that, in these patients, topiramate appeared to have a positive effect on reducing self-abusive behavior, improving mood, and stabilizing weight.
ISSN:0887-8994
1873-5150
DOI:10.1016/S0887-8994(02)00490-3